CJC-1295
WELL RESEARCHEDShort-acting growth hormone releasing hormone analog | Modified GRF 1-29
By the INFOPEPTIDOS editorial team · content based on scientific literature.
Updated: August 2026.
Key points
- What it is: GHRH analog (Mod GRF 1-29) that stimulates growth hormone.
- Main use: growth hormone, recovery and body composition.
- Typical dose: 100–300 mcg by subcutaneous injection.
- Key result: raises baseline GH and IGF-1 production.
- Common effects: mild; redness, occasional fluid retention.
- Comparison: combined with Ipamorelin (GHRP) for a synergistic effect on GH.
- Status: not FDA-approved.
Technical data: Molecular formula C165H269N47O46 · Molecular weight 3647.2 g/mol. Source: PubChem.
Overview
What is CJC-1295?
CJC-1295 without DAC, also known as Modified GRF 1-29 (Mod GRF 1-29), is a synthetic analog of growth hormone releasing hormone (GHRH). This short-acting variant stimulates pulsatile growth hormone release, mimicking the body's natural GH secretion patterns. Unlike the DAC-modified version, it has a short half-life of about 30 minutes, allowing more precise control over GH pulses and reducing the risk of receptor desensitization.
Key benefits
Preserves natural GH pulsatility, minimal side effects, no receptor desensitization and precise control over GH release.
Mechanism of action
It binds to GHRH receptors on somatotroph cells, stimulating cAMP production and triggering growth hormone release in physiological pulses.
Quick start guide
Dosing protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Standard | 100–300 mcg | 1–2 times/day (depending on variant) | 8–12 weeks |
The DAC variant has a longer half-life. The specific dose must be assessed by a healthcare professional.
Reconstitution: units in the syringe
Example with a 5 mg vial + 2 ml of bacteriostatic water → a 2.5 mg/ml solution. On a U-100 insulin syringe (100 units = 1 ml):
| Dose | Volume | Units (U-100) |
|---|---|---|
| 100 mcg | 0.04 ml | 4 U |
| 200 mcg | 0.08 ml | 8 U |
| 300 mcg | 0.12 ml | 12 U |
Is your vial or water different? Calculate the exact units below.
🧮 Calculate your exact syringe dose →CJC-1295 vs Ipamorelin
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Class | GHRH analog | GHRP (secretagogue) |
| Action | Raises baseline GH | Triggers GH pulses |
| Half-life | Long (with DAC) | Short |
| Stackable | Yes, with Ipamorelin | Yes, with CJC-1295 |
⚠️ Who should NOT use it
- People with active cancer — increasing GH is discouraged.
- Pregnancy or breastfeeding.
- Always under the supervision of a healthcare professional.
What to expect
- Day 1-7: better sleep quality; vivid dreams are common due to improved REM sleep.
- Week 2-4: better recovery after workouts, less soreness and better pumps.
- Week 4-8: noticeable improvements in skin quality and slight body composition changes.
- Week 8-12: more significant lean mass gains, fat loss and greater joint comfort.
- Week 12 onward: continued gradual improvements in body composition and well-being.
Side effects & safety
- Generally well tolerated, with minimal side effects at recommended doses.
- May cause temporary facial flushing or warmth for 5-10 minutes after injection.
- Monitor blood glucose if diabetic: GH can affect insulin sensitivity.
- Not recommended for people with active cancer due to its growth-promoting effects.
- Avoid if you have diabetic retinopathy or severe kidney disease.
- Allergic reaction: rash, itching or swelling.
- Swelling, numbness or tingling in the hands (possible carpal tunnel syndrome).
- Persistent increase in thirst, urination or blood sugar levels.
- Vision changes, especially if you have diabetic retinopathy.
- If you are pregnant, breastfeeding or planning a pregnancy.
Frequently asked questions
What is CJC-1295?
CJC-1295 (without DAC), also called Mod GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH) that stimulates pulsatile GH release.
What is CJC-1295 researched for?
It is studied for growth hormone stimulation, recovery and body composition.
How does CJC-1295 work?
It binds to GHRH receptors on the pituitary's somatotroph cells and triggers GH release in physiological pulses.
How long does CJC-1295 take to work?
GH elevation occurs in about 30 minutes, IGF-1 increase in 2-4 weeks and body composition changes in 6-12 weeks.
What is the usual CJC-1295 dose?
In the without-DAC version, around 100 mcg, 2-3 times a day. The schedule is set by a professional.
How is CJC-1295 administered?
Subcutaneously; usually in the morning, after training and before bed.
How is CJC-1295 stored?
Refrigerated, using it within 30 days after reconstitution. See the storage guide.
What are the side effects of CJC-1295?
Usually well tolerated; temporary facial flushing may appear after injection.
Which peptides is CJC-1295 combined with?
The most popular combination is CJC-1295 with Ipamorelin, which boosts GH release.
What is the difference between CJC-1295 with and without DAC?
The DAC version has a very long half-life; the version without DAC lasts about 30 minutes, which is more physiological and controllable.
Is CJC-1295 approved?
It is not FDA-approved for human use.
Research areas
- Growth hormone stimulation
- Body composition
- Physical recovery
- Sleep quality
- IGF-1 levels
Related peptides
- Ipamorelin — Selective GHRP; classic combination with CJC-1295.
- Sermorelin — GHRH 1-29 analog of the GH axis.
- Tesamorelin — GHRH analog researched for visceral fat.
Related articles
Related topics
- CJC-1295 and Ipamorelin
- CJC-1295 without DAC
- CJC-1295 dose
- CJC-1295 and muscle mass
- CJC-1295 and growth hormone
- CJC-1295 and recovery
Summary
What it is: GHRH analog (Mod GRF 1-29) without DAC.
How it is researched: Subcutaneous, ~100 mcg, 2-3 times a day.
Key features: Releases GH in physiological pulses; short half-life. Not FDA-approved.
Related peptides: Ipamorelin, Sermorelin and Tesamorelin.
References
- Teichman SL et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. PubMed · DOI
- Van Hout MC et al. (2016). Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. PubMed · DOI
- Memdouh S et al. (2021). Advances in the detection of growth hormone releasing hormone synthetic analogs. Drug Test Anal. PubMed · DOI
- Timms M et al. (2019). An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. Drug Test Anal. PubMed · DOI
Studies compiled from PubMed for informational purposes; many are preclinical or research-stage and do not constitute medical advice.